Imperial College London
Alternate

ProfessorStuartCook

Faculty of Medicine, Institute of Clinical Sciences

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 3313 1346stuart.cook

 
 
//

Location

 

RF 16Sydney StreetRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sweeney:2020:10.15252/emmm.201910865,
author = {Sweeney, M and Corden, B and Cook, SA},
doi = {10.15252/emmm.201910865},
journal = {EMBO Molecular Medicine},
pages = {1--26},
title = {Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?},
url = {http://dx.doi.org/10.15252/emmm.201910865},
volume = {12},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Cardiac fibrosis is central to the pathology of heart failure, particularly heart failure with preserved ejection fraction (HFpEF). Irrespective of the underlying profibrotic condition (e.g. ageing, diabetes, hypertension), maladaptive cardiac fibrosis is defined by the transformation of resident fibroblasts to matrix-secreting myofibroblasts. Numerous profibrotic factors have been identified at the molecular level (e.g. TGFβ, IL11, AngII), which activate gene expression programs for myofibroblast activation. A number of existing HF therapies indirectly target fibrotic pathways; however, despite multiple clinical trials in HFpEF, a specific clinically effective antifibrotic therapy remains elusive. Therapeutic inhibition of TGFβ, the master-regulator of fibrosis, has unfortunately proven toxic and ineffective in clinical trials to date, and new approaches are needed. In this review, we discuss the pathophysiology and clinical implications of interstitial fibrosis in HFpEF. We provide an overview of trials targeting fibrosis in HFpEF to date and discuss the promise of potential new therapeutic approaches and targets in the context of underlying molecular mechanisms.
AU  - Sweeney,M
AU  - Corden,B
AU  - Cook,SA
DO  - 10.15252/emmm.201910865
EP  - 26
PY  - 2020///
SN  - 1757-4676
SP  - 1
TI  - Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
T2  - EMBO Molecular Medicine
UR  - http://dx.doi.org/10.15252/emmm.201910865
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000571246700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.embopress.org/doi/full/10.15252/emmm.201910865
UR  - http://hdl.handle.net/10044/1/98480
VL  - 12
ER  -
Download